News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millennium: The Takeda Oncology Company Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma



6/28/2012 9:42:07 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating MLN9708 in patients with relapsed and/or refractory multiple myeloma. The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe, North America, Latin America and the Asia-Pacific region.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES